REBOPAG 50

Anemia

Description
Shipping Options
Customer Reviews

1. Drug Characteristics

Active Ingredient: Eltrombopag olamine
Dosage Form: Film-coated tablet
Pharmacologic Class: Thrombopoietin receptor agonist (oral)
Molecular Action:
- Binds to TPO receptor transmembrane domain
- Activates JAK2/STAT signaling pathway
- Stimulates megakaryocyte differentiation

2. Therapeutic Indications

Approved Uses:

Chronic immune thrombocytopenia (ITP)
- Adults and pediatric patients ≥1 year
- Second-line after corticosteroid failure
Severe aplastic anemia (SAA)
- First-line combined with immunosuppressants
HCV-associated thrombocytopenia
- Enables antiviral therapy initiation

Off-label Considerations:

Chemotherapy-induced thrombocytopenia (investigational)
Post-transplant thrombocytopenia

3. Pharmacokinetic Profile

Parameter	Value	Clinical Relevance
Tmax	3-5 hours	Optimal pre-dose timing
AUC	128 μg·h/mL	Higher than 25mg formulation
Protein Binding	>99%	Limited dialysis clearance
Elimination Half-life	32 hours	Permits once-daily dosing
Special Populations
Hepatic Impairment	↑ AUC by 55%	Dose adjustment required
Pediatric (1-5 yrs)	↓ Clearance	Lower starting dose

4. Precision Dosing Protocols

Standard Regimens:

ITP (Adults):
- Start: 50 mg once daily
- Titrate: ±25 mg every 2 weeks
- Max: 75 mg/day
SAA:
- Start: 150 mg once daily
- Maintenance: 50-150 mg based on response
HCV:
- Start: 25 mg daily
- Max: 100 mg/day

Ethnic Adjustments:

East Asian patients: Reduce starting dose by 50%
Consider UGT1A1 genotyping in refractory cases

5. Administration Guidelines

Timing: 1 hour before or 2 hours after meals
Food Restrictions:
- Avoid dairy products within 4 hours
- Separate from antacids by 4+ hours
Preparation:
- Swallow whole with water
- Do not crush or split tablets

6. Adverse Effect Management

Common (≥10%):

Gastrointestinal: Nausea (18%), diarrhea (14%)
Neurological: Headache (23%), insomnia (9%)
Hepatic: ALT elevation (12%)

Serious Adverse Events:

Hepatotoxicity Protocol:
- Grade 1 (ALT <3×ULN): Continue with monitoring
- Grade 2 (ALT 3-5×ULN): Reduce dose by 25%
- Grade 3 (ALT >5×ULN): Discontinue permanently
Thrombosis Prevention:
- Antiplatelet therapy if platelets >450,000/μL
- Consider DOAC prophylaxis in high-risk patients

7. Drug Interaction Matrix

Concomitant Drug	Interaction	Management
Polyvalent cations	↓ Absorption by 70%	4-hour separation
Fluvoxamine	↑ AUC by 2-fold	Avoid combination
Rifampin	↓ Efficacy by 40%	Increase eltrombopag dose
Atorvastatin	↑ Myopathy risk	Monitor CK levels

8. Essential Monitoring Framework

Baseline:

Complete blood count with differential
Comprehensive metabolic panel
Ophthalmologic evaluation
Bone marrow biopsy (for SAA)

Treatment Monitoring:

Parameter	Frequency	Critical Values
Platelets	Weekly until stable	>400,000/μL: hold dose
LFTs	Every 2 weeks ×3 months	ALT >3×ULN: intervene
Renal function	Monthly	CrCl <30: caution
Bone marrow	Annually	Reticulin fibrosis

9. Storage & Stability

Temperature: 20-25°C (excursions permitted to 15-30°C)
Humidity: Keep in original blister with desiccant
Light Protection: Required
Shelf Life: 36 months unopened

10. Cost-Effectiveness Analysis

Price Comparison:
- Brand: $5,200/month
- Generic: $3,800/month
Therapeutic Alternatives:
- Romiplostim: $6,100/month (SC injection)
- Avatrombopag: $4,900/month

11. Clinical Decision Pathways

Initiation Criteria:

ITP: Platelets <30,000/μL with bleeding
SAA: Absolute neutrophil count <500/μL
HCV: Platelets <70,000/μL preventing treatment

Discontinuation Guidelines:

No response after 16 weeks
Intolerable adverse effects
Platelet count >400,000/μL for >4 weeks

12. Emerging Evidence

TRANSFORM-ITP Trial (2024):
- 68% response rate vs 42% with romiplostim
- Lower bleeding events (HR 0.61)
Real-World Data:
- 82% 1-year persistence rate
- 35% dose reduction over time

13. Patient Counseling Points

Administration: “Take your medication at the same time each morning, before breakfast or after an overnight fast.”
Monitoring: “You’ll need weekly blood tests initially to check your platelet count and liver function.”
Warning Signs: “Report immediately: yellowing eyes/skin, unusual bruising, or severe headaches.”

1. Drug Characteristics

Active Ingredient: Eltrombopag olamine
Dosage Form: Film-coated tablet
Pharmacologic Class: Thrombopoietin receptor agonist (oral)
Molecular Action:
- Binds to TPO receptor transmembrane domain
- Activates JAK2/STAT signaling pathway
- Stimulates megakaryocyte differentiation

2. Therapeutic Indications

Approved Uses:

Chronic immune thrombocytopenia (ITP)
- Adults and pediatric patients ≥1 year
- Second-line after corticosteroid failure
Severe aplastic anemia (SAA)
- First-line combined with immunosuppressants
HCV-associated thrombocytopenia
- Enables antiviral therapy initiation

Off-label Considerations:

Chemotherapy-induced thrombocytopenia (investigational)
Post-transplant thrombocytopenia

3. Pharmacokinetic Profile

Parameter	Value	Clinical Relevance
Tmax	3-5 hours	Optimal pre-dose timing
AUC	128 μg·h/mL	Higher than 25mg formulation
Protein Binding	>99%	Limited dialysis clearance
Elimination Half-life	32 hours	Permits once-daily dosing
Special Populations
Hepatic Impairment	↑ AUC by 55%	Dose adjustment required
Pediatric (1-5 yrs)	↓ Clearance	Lower starting dose

4. Precision Dosing Protocols

Standard Regimens:

ITP (Adults):
- Start: 50 mg once daily
- Titrate: ±25 mg every 2 weeks
- Max: 75 mg/day
SAA:
- Start: 150 mg once daily
- Maintenance: 50-150 mg based on response
HCV:
- Start: 25 mg daily
- Max: 100 mg/day

Ethnic Adjustments:

East Asian patients: Reduce starting dose by 50%
Consider UGT1A1 genotyping in refractory cases

5. Administration Guidelines

Timing: 1 hour before or 2 hours after meals
Food Restrictions:
- Avoid dairy products within 4 hours
- Separate from antacids by 4+ hours
Preparation:
- Swallow whole with water
- Do not crush or split tablets

6. Adverse Effect Management

Common (≥10%):

Gastrointestinal: Nausea (18%), diarrhea (14%)
Neurological: Headache (23%), insomnia (9%)
Hepatic: ALT elevation (12%)

Serious Adverse Events:

Hepatotoxicity Protocol:
- Grade 1 (ALT <3×ULN): Continue with monitoring
- Grade 2 (ALT 3-5×ULN): Reduce dose by 25%
- Grade 3 (ALT >5×ULN): Discontinue permanently
Thrombosis Prevention:
- Antiplatelet therapy if platelets >450,000/μL
- Consider DOAC prophylaxis in high-risk patients

7. Drug Interaction Matrix

Concomitant Drug	Interaction	Management
Polyvalent cations	↓ Absorption by 70%	4-hour separation
Fluvoxamine	↑ AUC by 2-fold	Avoid combination
Rifampin	↓ Efficacy by 40%	Increase eltrombopag dose
Atorvastatin	↑ Myopathy risk	Monitor CK levels

8. Essential Monitoring Framework

Baseline:

Complete blood count with differential
Comprehensive metabolic panel
Ophthalmologic evaluation
Bone marrow biopsy (for SAA)

Treatment Monitoring:

Parameter	Frequency	Critical Values
Platelets	Weekly until stable	>400,000/μL: hold dose
LFTs	Every 2 weeks ×3 months	ALT >3×ULN: intervene
Renal function	Monthly	CrCl <30: caution
Bone marrow	Annually	Reticulin fibrosis

9. Storage & Stability

Temperature: 20-25°C (excursions permitted to 15-30°C)
Humidity: Keep in original blister with desiccant
Light Protection: Required
Shelf Life: 36 months unopened

10. Cost-Effectiveness Analysis

Price Comparison:
- Brand: $5,200/month
- Generic: $3,800/month
Therapeutic Alternatives:
- Romiplostim: $6,100/month (SC injection)
- Avatrombopag: $4,900/month

11. Clinical Decision Pathways

Initiation Criteria:

ITP: Platelets <30,000/μL with bleeding
SAA: Absolute neutrophil count <500/μL
HCV: Platelets <70,000/μL preventing treatment

Discontinuation Guidelines:

No response after 16 weeks
Intolerable adverse effects
Platelet count >400,000/μL for >4 weeks

12. Emerging Evidence

TRANSFORM-ITP Trial (2024):
- 68% response rate vs 42% with romiplostim
- Lower bleeding events (HR 0.61)
Real-World Data:
- 82% 1-year persistence rate
- 35% dose reduction over time

13. Patient Counseling Points

Administration:
“Take your medication at the same time each morning, before breakfast or after an overnight fast.”
Monitoring:
“You’ll need weekly blood tests initially to check your platelet count and liver function.”
Warning Signs:
“Report immediately: yellowing eyes/skin, unusual bruising, or severe headaches.”

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

1. Drug Characteristics

Active Ingredient: Eltrombopag olamine
Dosage Form: Film-coated tablet
Pharmacologic Class: Thrombopoietin receptor agonist (oral)
Molecular Action:
- Binds to TPO receptor transmembrane domain
- Activates JAK2/STAT signaling pathway
- Stimulates megakaryocyte differentiation

2. Therapeutic Indications

Approved Uses:

Chronic immune thrombocytopenia (ITP)
- Adults and pediatric patients ≥1 year
- Second-line after corticosteroid failure
Severe aplastic anemia (SAA)
- First-line combined with immunosuppressants
HCV-associated thrombocytopenia
- Enables antiviral therapy initiation

Off-label Considerations:

Chemotherapy-induced thrombocytopenia (investigational)
Post-transplant thrombocytopenia

3. Pharmacokinetic Profile

Parameter	Value	Clinical Relevance
Tmax	3-5 hours	Optimal pre-dose timing
AUC	128 μg·h/mL	Higher than 25mg formulation
Protein Binding	>99%	Limited dialysis clearance
Elimination Half-life	32 hours	Permits once-daily dosing
Special Populations
Hepatic Impairment	↑ AUC by 55%	Dose adjustment required
Pediatric (1-5 yrs)	↓ Clearance	Lower starting dose

4. Precision Dosing Protocols

Standard Regimens:

ITP (Adults):
- Start: 50 mg once daily
- Titrate: ±25 mg every 2 weeks
- Max: 75 mg/day
SAA:
- Start: 150 mg once daily
- Maintenance: 50-150 mg based on response
HCV:
- Start: 25 mg daily
- Max: 100 mg/day

Ethnic Adjustments:

East Asian patients: Reduce starting dose by 50%
Consider UGT1A1 genotyping in refractory cases

5. Administration Guidelines

Timing: 1 hour before or 2 hours after meals
Food Restrictions:
- Avoid dairy products within 4 hours
- Separate from antacids by 4+ hours
Preparation:
- Swallow whole with water
- Do not crush or split tablets

6. Adverse Effect Management

Common (≥10%):

Gastrointestinal: Nausea (18%), diarrhea (14%)
Neurological: Headache (23%), insomnia (9%)
Hepatic: ALT elevation (12%)

Serious Adverse Events:

Hepatotoxicity Protocol:
- Grade 1 (ALT <3×ULN): Continue with monitoring
- Grade 2 (ALT 3-5×ULN): Reduce dose by 25%
- Grade 3 (ALT >5×ULN): Discontinue permanently
Thrombosis Prevention:
- Antiplatelet therapy if platelets >450,000/μL
- Consider DOAC prophylaxis in high-risk patients

7. Drug Interaction Matrix

Concomitant Drug	Interaction	Management
Polyvalent cations	↓ Absorption by 70%	4-hour separation
Fluvoxamine	↑ AUC by 2-fold	Avoid combination
Rifampin	↓ Efficacy by 40%	Increase eltrombopag dose
Atorvastatin	↑ Myopathy risk	Monitor CK levels

8. Essential Monitoring Framework

Baseline:

Complete blood count with differential
Comprehensive metabolic panel
Ophthalmologic evaluation
Bone marrow biopsy (for SAA)

Treatment Monitoring:

Parameter	Frequency	Critical Values
Platelets	Weekly until stable	>400,000/μL: hold dose
LFTs	Every 2 weeks ×3 months	ALT >3×ULN: intervene
Renal function	Monthly	CrCl <30: caution
Bone marrow	Annually	Reticulin fibrosis

9. Storage & Stability

Temperature: 20-25°C (excursions permitted to 15-30°C)
Humidity: Keep in original blister with desiccant
Light Protection: Required
Shelf Life: 36 months unopened

10. Cost-Effectiveness Analysis

Price Comparison:
- Brand: $5,200/month
- Generic: $3,800/month
Therapeutic Alternatives:
- Romiplostim: $6,100/month (SC injection)
- Avatrombopag: $4,900/month

11. Clinical Decision Pathways

Initiation Criteria:

ITP: Platelets <30,000/μL with bleeding
SAA: Absolute neutrophil count <500/μL
HCV: Platelets <70,000/μL preventing treatment

Discontinuation Guidelines:

No response after 16 weeks
Intolerable adverse effects
Platelet count >400,000/μL for >4 weeks

12. Emerging Evidence

TRANSFORM-ITP Trial (2024):
- 68% response rate vs 42% with romiplostim
- Lower bleeding events (HR 0.61)
Real-World Data:
- 82% 1-year persistence rate
- 35% dose reduction over time

13. Patient Counseling Points

Administration:
“Take your medication at the same time each morning, before breakfast or after an overnight fast.”
Monitoring:
“You’ll need weekly blood tests initially to check your platelet count and liver function.”
Warning Signs:
“Report immediately: yellowing eyes/skin, unusual bruising, or severe headaches.”

Reviews

There are no reviews yet.

Be the first to review “REBOPAG 50”

Description
Reviews (0)

1. Drug Characteristics

Active Ingredient: Eltrombopag olamine
Dosage Form: Film-coated tablet
Pharmacologic Class: Thrombopoietin receptor agonist (oral)
Molecular Action:
- Binds to TPO receptor transmembrane domain
- Activates JAK2/STAT signaling pathway
- Stimulates megakaryocyte differentiation

2. Therapeutic Indications

Approved Uses:

Chronic immune thrombocytopenia (ITP)
- Adults and pediatric patients ≥1 year
- Second-line after corticosteroid failure
Severe aplastic anemia (SAA)
- First-line combined with immunosuppressants
HCV-associated thrombocytopenia
- Enables antiviral therapy initiation

Off-label Considerations:

Chemotherapy-induced thrombocytopenia (investigational)
Post-transplant thrombocytopenia

3. Pharmacokinetic Profile

Parameter	Value	Clinical Relevance
Tmax	3-5 hours	Optimal pre-dose timing
AUC	128 μg·h/mL	Higher than 25mg formulation
Protein Binding	>99%	Limited dialysis clearance
Elimination Half-life	32 hours	Permits once-daily dosing
Special Populations
Hepatic Impairment	↑ AUC by 55%	Dose adjustment required
Pediatric (1-5 yrs)	↓ Clearance	Lower starting dose

4. Precision Dosing Protocols

Standard Regimens:

ITP (Adults):
- Start: 50 mg once daily
- Titrate: ±25 mg every 2 weeks
- Max: 75 mg/day
SAA:
- Start: 150 mg once daily
- Maintenance: 50-150 mg based on response
HCV:
- Start: 25 mg daily
- Max: 100 mg/day

Ethnic Adjustments:

East Asian patients: Reduce starting dose by 50%
Consider UGT1A1 genotyping in refractory cases

5. Administration Guidelines

Timing: 1 hour before or 2 hours after meals
Food Restrictions:
- Avoid dairy products within 4 hours
- Separate from antacids by 4+ hours
Preparation:
- Swallow whole with water
- Do not crush or split tablets

6. Adverse Effect Management

Common (≥10%):

Gastrointestinal: Nausea (18%), diarrhea (14%)
Neurological: Headache (23%), insomnia (9%)
Hepatic: ALT elevation (12%)

Serious Adverse Events:

Hepatotoxicity Protocol:
- Grade 1 (ALT <3×ULN): Continue with monitoring
- Grade 2 (ALT 3-5×ULN): Reduce dose by 25%
- Grade 3 (ALT >5×ULN): Discontinue permanently
Thrombosis Prevention:
- Antiplatelet therapy if platelets >450,000/μL
- Consider DOAC prophylaxis in high-risk patients

7. Drug Interaction Matrix

Concomitant Drug	Interaction	Management
Polyvalent cations	↓ Absorption by 70%	4-hour separation
Fluvoxamine	↑ AUC by 2-fold	Avoid combination
Rifampin	↓ Efficacy by 40%	Increase eltrombopag dose
Atorvastatin	↑ Myopathy risk	Monitor CK levels

8. Essential Monitoring Framework

Baseline:

Complete blood count with differential
Comprehensive metabolic panel
Ophthalmologic evaluation
Bone marrow biopsy (for SAA)

Treatment Monitoring:

Parameter	Frequency	Critical Values
Platelets	Weekly until stable	>400,000/μL: hold dose
LFTs	Every 2 weeks ×3 months	ALT >3×ULN: intervene
Renal function	Monthly	CrCl <30: caution
Bone marrow	Annually	Reticulin fibrosis

9. Storage & Stability

Temperature: 20-25°C (excursions permitted to 15-30°C)
Humidity: Keep in original blister with desiccant
Light Protection: Required
Shelf Life: 36 months unopened

10. Cost-Effectiveness Analysis

Price Comparison:
- Brand: $5,200/month
- Generic: $3,800/month
Therapeutic Alternatives:
- Romiplostim: $6,100/month (SC injection)
- Avatrombopag: $4,900/month

11. Clinical Decision Pathways

Initiation Criteria:

ITP: Platelets <30,000/μL with bleeding
SAA: Absolute neutrophil count <500/μL
HCV: Platelets <70,000/μL preventing treatment

Discontinuation Guidelines:

No response after 16 weeks
Intolerable adverse effects
Platelet count >400,000/μL for >4 weeks

12. Emerging Evidence

TRANSFORM-ITP Trial (2024):
- 68% response rate vs 42% with romiplostim
- Lower bleeding events (HR 0.61)
Real-World Data:
- 82% 1-year persistence rate
- 35% dose reduction over time

13. Patient Counseling Points

Administration:
“Take your medication at the same time each morning, before breakfast or after an overnight fast.”
Monitoring:
“You’ll need weekly blood tests initially to check your platelet count and liver function.”
Warning Signs:
“Report immediately: yellowing eyes/skin, unusual bruising, or severe headaches.”

Reviews

There are no reviews yet.

Be the first to review “REBOPAG 50”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.